Paradoxical Aortic Stiffening and Subsequent Cardiac Dysfunction in Hutchinson-Gilford Progeria Syndrome

Sae‐Il Murtada, Yuki I. Kawamura, Alexander W. Caulk, H. Amadzadeh, Nicole Mikush, Kristin M. Zimmerman Savill, Dillon Kavanagh, Dar Weiss, Marcos Latorre, Z.w. Zhang, Gerald S. Shadel, Demetrios T. Braddock, Jay D. Humphrey

Abstract

Hutchinson-Gilford Progeria Syndrome (HGPS) is an ultra-rare disorder with devastating sequelae resulting in early death, presently believed to stem primarily from heart failure secondary to central arterial stiffening. We analyze novel longitudinal cardiovascular data from a mouse model of HGPS ($Lmna^{G609G/G609G}$) using allometric scaling and advanced computational modelling and show that a late-stage increase in pulse wave velocity, with associated diastolic dysfunction but preserved systolic function, emerges with a loss of aortic function, independent of sex. Specifically, there is a dramatic late-stage loss of smooth muscle function and cells and an excessive accumulation of proteoglycans along the entire aorta, which result in a loss of biomechanical function (contractility and elastic energy storage) and marked structural stiffening despite a distinctly low intrinsic material stiffness that is consistent with the lack of functional lamin A. Importantly, vascular function appears to be normal within the low stress environment of development, only to succumb progressively to pressure-related effects of the lamin A mutation and become extreme in the peri-morbid period. Because the dramatic life-threatening aortic phenotype manifests during the last quarter of life there may be a therapeutic window in maturity that could alleviate concerns with therapies administered during early periods of arterial development.

Introduction

Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare genetic "premature aging" disease caused by a mutation in the LMNA gene, leading to the production of progerin. Children with HGPS typically die in their early teens from heart failure or stroke. While arterial stiffening is a known hallmark, the mechanical progression—whether it stems from intrinsic material changes or structural remodeling—has remained unclear. This study investigates the biomechanical collapse of the aorta in a mouse model to bridge the gap between genetic mutation and cardiovascular failure.

Methodology and Allometric Scaling

Researchers utilized a multi-scale approach to study the $Lmna^{G609G/G609G}$ progeria mouse model. Key techniques included high-frequency ultrasound (echocardiography) and micro-CT to track heart function and arterial dimensions. A critical component of the analysis was allometric scaling. Because progeria mice are significantly smaller than healthy littermates, metrics like cardiac output (CO) were adjusted based on body mass to distinguish pathological decline from changes simply due to smaller size.

Allometric scaling of cardiac output (CO) relative to body mass, showing the deviation of progeroid mice (black circles) from the expected growth curve.

Additionally, the team performed ex vivo biaxial biomechanical testing and developed a particle-based computational model of the aortic wall to simulate the contributions of elastin, collagen, and proteoglycans to vessel stiffness.

Results: The Mechanical Paradox and Cardiac Decline

The study revealed a "mechanical paradox": the progeroid aorta becomes structurally stiffer, yet its intrinsic material stiffness is abnormally low. This structural stiffening is driven by a massive accumulation of proteoglycans and a loss of smooth muscle cells, which thickens the wall and prevents efficient elastic energy storage.

Comprehensive cardiovascular phenotype of HGPS mice, illustrating the decline in body mass (A), heart morphology (B), cardiac output (E), and the sharp increase in pulse wave velocity (N) alongside diastolic dysfunction.

Key Findings:

  • Pulse Wave Velocity (PWV): PWV was dramatically higher in late-stage progeria (~6.16 m/s) compared to controls (~3.68 m/s), indicating severe arterial stiffening.
  • Systolic vs. Diastolic Function: Surprisingly, systolic pumping ability remained normal until near death. The primary failure was diastolic—the heart could not fill properly due to rapid pressure wave reflections from the stiffened aorta.
  • Late-Life Decline: Vascular function remained remarkably normal during development, with the catastrophic decline occurring only in the final 25% of the lifespan. This suggests the damage is a cumulative response to mechanical stress over time.

Discussion and Therapeutic Implications

The findings suggest that the life-threatening aortic phenotype in HGPS is not an inherent developmental defect but a progressive failure. The progeroid aorta undergoes a "proteoglycan pump" effect, where glycosaminoglycans attract water and physically push elastic layers apart, destroying the vessel's ability to store energy.

Because this decline manifests late in life, there may be a therapeutic window in early maturity. Interventions aimed at protecting smooth muscle cell phenotype and preventing proteoglycan accumulation during this period could potentially extend the lifespan of those affected by HGPS, avoiding the complications of treating developing arteries in early childhood.

Summary updated

Abstract

SUMMARY Hutchinson-Gilford Progeria Syndrome (HGPS) is an ultra-rare disorder with devastating sequelae resulting in early death, presently believed to stem primarily from heart failure secondary to central arterial stiffening. We analyze novel longitudinal cardiovascular data from a mouse model of HGPS ( Lmna G609G/G609G ) using allometric scaling and advanced computational modelling and show that a late-stage increase in pulse wave velocity, with associated diastolic dysfunction but preserved systolic function, emerges with a loss of aortic function, independent of sex. Specifically, there is a dramatic late-stage loss of smooth muscle function and cells and an excessive accumulation of proteoglycans along the entire aorta, which result in a loss of biomechanical function (contractility and elastic energy storage) and marked structural stiffening despite a distinctly low intrinsic material stiffness that is consistent with the lack of functional lamin A. Importantly, vascular function appears to be normal within the low stress environment of development, only to succumb progressively to pressure-related effects of the lamin A mutation and become extreme in the peri-morbid period. Because the dramatic life-threatening aortic phenotype manifests during the last quarter of life there may be a therapeutic window in maturity that could alleviate concerns with therapies administered during early periods of arterial development. Disclosures D.T.B is an equity holder in, and receives research and consulting support from, Inozyme Pharma, Inc. for therapeutics for ENPP1 deficiency. None of the other authors declare any conflict, financial or otherwise.
BibTeX
@article{murtada2020paradoxical,
  author = {Sae‐Il Murtada and Yuki I. Kawamura and Alexander W. Caulk and H. Amadzadeh and Nicole Mikush and Kristin M. Zimmerman Savill and Dillon Kavanagh and Dar Weiss and Marcos Latorre and Z.W. Zhang and Gerald S. Shadel and Demetrios T. Braddock and Jay D. Humphrey},
  title = {{Paradoxical Aortic Stiffening and Subsequent Cardiac Dysfunction in Hutchinson-Gilford Progeria Syndrome}},
  journal = {Journal of The Royal Society Interface},
  year = {2020},
  doi = {10.1098/rsif.2020.0066},
}
Figure